✦ LIBER ✦

474: Assessing safety and efficacy of Neoral®/everolimus maintenance therapy in cardiac transplant recipients: 12 month data

✍ Scribed by H. Ross; J. Burton; P. Pflugfelder; M. Cantarovich; A. Ignaszewski; J. Howlett; M. White; H. Haddad; R. Dorent; C. Sips; M. Vaillancourt

Book ID: 116519994
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 63 KB
Volume: 26
Category: Article
ISSN: 1557-3117
DOI: 10.1016/j.healun.2006.11.497

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, tolerability, and efficacy of ev

Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results

✍ Gary Levy; Heinz Schmidli; Jeffrey Punch; Elizabeth Tuttle-Newhall; David Mayer; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 grou

12-month safety and efficacy of everolim

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

✍ Helio Tedesco-Silva Jr; Stefan Vitko; Julio Pascual; Josette Eris; John C. Magee 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 504 KB

Safety and efficacy of everolimus (RAD)

Safety and efficacy of everolimus (RAD) as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: six-month analysis

✍ H. Eisen; R. Dorent; D. Mancini; H. Valantine; M. Vigano; R. Starling; J. Lind; 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 67 KB

A 12-month, multicenter, randomized, ada

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-month outcomes

✍ H. Ross; M. Cantarovich; J. Arizon; J. Orus; L. Straatman; J. Howlett; E. Lage; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 66 KB

A 12-month, multicenter, randomized, ada

A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2 hour monitoring of neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction

✍ M Cantarovich; H Ross; J Arizon; J Orus; L Straatman; J Howlett; E Lage; M Cresp 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Efficacy and Safety of Enteric-Coated My

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients: Pooled Data From Three 12-Month Multicenter, Open-Label, Prospective Studies

✍ C. Legendre; D. Cohen; M. Zeier; L. Rostaing; K. Budde 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 87 KB